newsfilter
← Latest News
Business Wire·

AVROBIO to Present Clinical and Preclinical Data from Lysosomal Disorder Gene Therapy Pipeline at WORLDSymposium™ 2023

Four platform presentations and two posters with data on AVROBIO's lysosomal disorder programs to be presented AVROBIO, Inc. (NASDAQ:AVRO), a leading clinical-stage gene therapy company working to free people from a